OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 14.0% in December

OPKO Health, Inc. (NASDAQ:OPK) saw a large drop in short interest in December. As of December 15th, there was short interest totalling 84,800,000 shares, a drop of 14.0% from the November 30th total of 98,570,000 shares. Based on an average daily volume of 3,950,000 shares, the short-interest ratio is presently 21.5 days. Currently, 27.4% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Thursday, December 26th. Finally, HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th.

OPKO Health Price Performance

OPKO Health stock opened at $1.47 on Wednesday. The company has a market capitalization of $1.00 billion, a PE ratio of -7.74 and a beta of 1.62. OPKO Health has a 12-month low of $0.85 and a 12-month high of $1.76. The firm’s fifty day moving average is $1.55 and its 200 day moving average is $1.49. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Insider Activity

In other news, CEO Phillip Md Et Al Frost bought 100,000 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the completion of the transaction, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. This trade represents a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have purchased 1,304,255 shares of company stock worth $2,024,605. Corporate insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several institutional investors have recently made changes to their positions in OPK. Rubric Capital Management LP increased its position in OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the period. Y.D. More Investments Ltd bought a new stake in shares of OPKO Health during the second quarter valued at approximately $1,840,000. PFG Investments LLC raised its position in shares of OPKO Health by 10.4% during the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock worth $1,581,000 after purchasing an additional 100,125 shares during the period. Finally, Clearline Capital LP bought a new position in shares of OPKO Health in the 3rd quarter worth $1,083,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.